Abstract
No AccessJournal of UrologyLetter to the Editor/errata1 Apr 2008Re: A Randomized Trial of Radical Radiotherapy for the Management of pT1G3 NXM0 Transitional Cell Carcinoma of the BladderS. J. Harland, H. Kynaston, K. Grigor, D. M. Wallace, C. Beacock, R. Kockelbergh, S. Clawson, T. Barlow, M. K. Parmar and G. O. Griffiths; National Cancer Research Institute Bladder Clinical Studies Group J Urol 2007; 178: 807–813 Donald L. Lamm Donald L. LammDonald L. Lamm More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2007.11.102AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail References 1 : The role of repeat transurethral resection in the management of high-risk superficial transitional cell bladder cancer. BJU Int2005; 96: 759. Google Scholar 2 : Clinical under staging of high risk nonmuscle invasive urothelial carcinoma treated with radical cystectomy. J Urol2001; 166: 490. Link, Google Scholar 3 : Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial. Lancet Oncol2006; 7: 43. Google Scholar 4 : Intravesical bacillus Calmette-Guerin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial. J Clin Oncol1995; 13: 1404. Google Scholar 5 : Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group study. J Urol2000; 163: 1124. Link, Google Scholar 6 : Intravesical bacillus Calmette-Guerin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. BJU Int2004; 93: 485. Google Scholar 7 : Management of stage T1 superficial bladder cancer with intravesical bacillus Calmette-Guerin therapy. J Urol1992; 148: 797. Link, Google Scholar 8 : Urologists’ attitudes to the management of bladder cancer. Br J Urol1992; 70: 522. Google Scholar 9 : Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol2002; 168: 1964. Link, Google Scholar 10 : The treated natural history of high risk superficial bladder cancer: 15-year outcome. J Urol1997; 158: 62. Link, Google Scholar 11 : Tumour progression and survival in patients with T1G3 bladder tumours: 15-year outcome. Br J Urol1997; 80: 762. Google Scholar 12 : A trial of bacillus Calmette-Guerin versus adriamycin in superficial bladder cancer: a South-West Oncology Group study. Urol Int1986; 41: 254. Google Scholar 13 : The role and impact of pathology review on stage and grade assessment of stages Ta and T1 bladder tumors: a combined analysis of 5 European Organization for Research and Treatment of Cancer trials. J Urol2000; 164: 1533. Link, Google Scholar BCG Oncology, Phoenix, Arizona© 2008 by American Urological AssociationFiguresReferencesRelatedDetails Volume 179Issue 4April 2008Page: 1639-1641 Advertisement Copyright & Permissions© 2008 by American Urological AssociationMetricsAuthor Information Donald L. Lamm More articles by this author Expand All Advertisement PDF downloadLoading ...
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call